Journal of Basic Research in Medical Sciences
J Basic Res Med Sci
Volume 13, Issue 4 (9-2026)
jbrms 2026, 13(4): 19-28 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Azizi E, Sharifi Z, Mozafari A, yarhosseini A, Norizadeh A, sharifi A et al . Effect of Risperidone Treatment on Hematological Indices in Schizophrenia Patients. jbrms 2026; 13 (4) :19-28
URL: http://jbrms.medilam.ac.ir/article-1-1082-en.html
URL: http://jbrms.medilam.ac.ir/article-1-1082-en.html
Esfandiar Azizi 
, Zahra Sharifi , Aliashraf Mozafari , Amir Yarhosseini , Ali Norizadeh , Ali Sharifi , Ali Seidkhani-Nahal
, Zahra Sharifi , Aliashraf Mozafari , Amir Yarhosseini , Ali Norizadeh , Ali Sharifi , Ali Seidkhani-Nahal
Department of Clinical Biochemistry, Faculty of Medical Sciences, Ilam University of Medical Sciences, Ilam, Iran , seidkhani-a@medilam.ac.ir
Abstract: (25 Views)
Introduction: Schizophrenia (SCZ) is a complex psychiatric disorder of unknown pathogenesis, characterized by a spectrum of cognitive, behavioral, and emotional dysfunctions. Recent studies have shown that SCZ is associated with immunological and hematological alterations. These alterations offer potential insights into the underlying biological mechanisms and may serve as biomarkers for diagnosis or therapeutic targets. Nonetheless, the relationship between these alterations and antipsychotic medications remains unclear. This study aimed to evaluate the effects of risperidone treatment on hematological inflammatory indices, complete blood count (CBC), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and mean platelet volume-to-lymphocyte ratio (MPVLR) in patients with schizophrenia.
Materials & Methods: The study group consisted of 44 SCZ and 44 age- and sex-matched healthy controls. Blood samples were collected from SCZ patients before and after three months of treatment, as well as from healthy individuals. In pre-treatment, risperidone monotherapy, and healthy control groups, CBC was performed, and PLR, NLR, and MPVLR were calculated. Clinical symptoms were evaluated by the Positive and Negative Syndrome Scale (PANSS) before and after treatment.
Results: Despite the reduction of NLR and PLR (p < 0.001 and p = 0.007, respectively), PLR remained significantly higher in post-treatment patients than in the healthy control group (p = 0.01). Given the NLR factor, no significant difference was observed between healthy control and post-treatment groups. There were no significant differences in the MPVLR factor among the three groups.
Conclusion: The findings of this study suggest that risperidone therapy resulted in a reduction in NLR and PLR changes with improvement in symptoms, indicating its immunomodulatory effects in SCZ treatment. Such an inexpensive CBC-derived ratio may be considered a monitoring biomarker for treatment responses
Materials & Methods: The study group consisted of 44 SCZ and 44 age- and sex-matched healthy controls. Blood samples were collected from SCZ patients before and after three months of treatment, as well as from healthy individuals. In pre-treatment, risperidone monotherapy, and healthy control groups, CBC was performed, and PLR, NLR, and MPVLR were calculated. Clinical symptoms were evaluated by the Positive and Negative Syndrome Scale (PANSS) before and after treatment.
Results: Despite the reduction of NLR and PLR (p < 0.001 and p = 0.007, respectively), PLR remained significantly higher in post-treatment patients than in the healthy control group (p = 0.01). Given the NLR factor, no significant difference was observed between healthy control and post-treatment groups. There were no significant differences in the MPVLR factor among the three groups.
Conclusion: The findings of this study suggest that risperidone therapy resulted in a reduction in NLR and PLR changes with improvement in symptoms, indicating its immunomodulatory effects in SCZ treatment. Such an inexpensive CBC-derived ratio may be considered a monitoring biomarker for treatment responses
Type of Study: Research |
Subject:
Medical immunology
Received: 2026/06/7 | Accepted: 2026/08/2 | Published: 2026/09/28
Received: 2026/06/7 | Accepted: 2026/08/2 | Published: 2026/09/28
References
1. McCutcheon RA, Marques TR, Howes OD. Schizophrenia—an overview. JAMA psychiatry. 2020;77(2):201–10. [DOI:10.1001/jamapsychiatry.2019.3360.]
2. Reynolds GP. The neurochemistry of schizophrenia. Psychiatry. 2005;4(10):21–5. [DOI:10.1016/j.mppsy.2008.07.014.]
3. Khandaker GM, Cousins L, Deakin J, Lennox BR, Yolken R, Jones PB. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry. 2015;2(3):258–70. [DOI:10.1016/S2215-0366(14)00122-9.]
4. Bora E. Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis. Psychol Med. 2019;49(12):1971–9. [DOI:10.1017/S0033291719001685.]
5. Hong J, Bang M. Anti-inflammatory Strategies for Schizophrenia: A Review of Evidence for Therapeutic Applications and Drug Repurposing. Clin Psychopharmacol Neurosci. 2020;18(1):10–24. [DOI:10.9758/cpn.2020.18.1.10.]
6. Pandurangi AK, Buckley PF. Inflammation, antipsychotic drugs, and evidence for effectiveness of anti-inflammatory agents in schizophrenia. Neuroinflammation and Schizophrenia. 2019:227–44. [DOI:10.1007/7854_2019_91.]
7. Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy. 2021;122(7):474–88. [DOI:10.4149/BLL_2021_078.]
8. Wang RH, Wen WX, Jiang ZP, Du ZP, Ma ZH, Lu AL, et al. The clinical value of neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR) and systemic inflammation response index (SIRI) for predicting the occurrence and severity of pneumonia in patients with intracerebral hemorrhage. Front Immunol. 2023;14:1115031. [DOI:10.3389/fimmu.2023.1115031.]
9. Thomas MR, Storey RF. The role of platelets in inflammation. Thromb Haemost. 2015;114(3):449–58. [DOI:10.1160/TH14-12-1067.]
10. Hou S, Gu Q, Yang T, Hou Y, Wang M, Pan Y, et al. A Multicenter Study on the Prognostic Value of Indicators Derived From Complete Blood Count in Glioblastoma. Mediators Inflamm. 2025;2025(1):5588098. [DOI:10.1155/mi/5588098.]
11. Leontiev D, Uthamacumaran A, Nagar R, Zenil H. Exhaustive Investigation of CBC-Derived Biomarker Ratios for Clinical Outcome Prediction: The RDW-to-MCHC Ratio as a Novel Mortality Predictor in Critical Care. arXiv preprint arXiv:251109583. 2025. [DOI:https://doi.org/10.48550/arXiv.2511.09583.]
12. Sokou R, Mantzios P, Palioura AE, Tsantes AG, Lianou A, Piovani D, et al. Diagnostic and Prognostic Value of Hematological Parameters in Necrotizing Enterocolitis: A Systematic Review. J Clin Med. 2025;14(7):2530. [DOI:10.3390/jcm14072530.]
13. Shukla R, Silvanus V, Dahal S, Sitaula P, Niraula Z, Gupta CK, et al. Complete blood count (CBC)-derived indices at admission and short-term outcomes in ICU patients: a retrospective study. Ann Med. 2025;57(1):2522963. [DOI:10.1080/07853890.2025.2522963.]
14. Seo I-H, Lee Y-J. Usefulness of complete blood count (CBC) to assess cardiovascular and metabolic diseases in clinical settings: a comprehensive literature review. Biomedicines. 2022;10(11):2697. [DOI:10.3390/biomedicines10112697.]
15. Balcioglu YH, Kirlioglu SS. C-Reactive Protein/Albumin and Neutrophil/Albumin Ratios as Novel Inflammatory Markers in Patients with Schizophrenia. Psychiatry Investig. 2020;17(9):902–10. [DOI:10.30773/pi.2020.0185.]
16. Gökçen O, Karataş KS, Akkuş M, Dönmez F, Yilmaz C, Konak MA. Tracking complete blood count-derived indices during transition to euthymia in bipolar disorder: a longitudinal study. Biomarkers in Medicine. 2025:1–9. [DOI:10.1080/17520363.2025.2511469.]
17. Novellino F, Donato A, Malara N, Madrigal JL, Donato G. Complete blood cell count-derived ratios can be useful biomarkers for neurological diseases. Int J Immunopathol Pharmacol. 2021;35:20587384211048264. [DOI:10.1177/20587384211048264.]
18. Wang L, Tian Z, Zuo L, He Y, Liu Y, Liu H. Correlation between complete blood count-derived inflammatory markers and sepsis-associated delirium in older patients: a retrospective analysis of the MIMIC-IV database. BMJ Open. 2025;15(9):e101960. [DOI:10.1136/bmjopen-2025-101960.]
19. Kayhan F, Gündüz Ş, Ersoy SA, Kandeğer A, Annagür BB. Relationships of neutrophil–lymphocyte and platelet–lymphocyte ratios with the severity of major depression. Psychiatry research. 2017;247:332–5. [DOI:10.1016/j.psychres.2016.11.016.]
20. Özdin S, Usta MB. A comparison of inflammatory markers in manic and euthymic states of bipolar disorder. Nordic Journal of Psychiatry. 2021;75(2):124–9. [DOI:10.1080/08039488.2020.1807048.]
21. Özdin S, Böke Ö. Neutrophil/lymphocyte, platelet/lymphocyte and monocyte/lymphocyte ratios in different stages of schizophrenia. Psychiatry research. 2019;271:131–5. [DOI:10.1016/j.psychres.2018.11.043.]
22. Dawidowski B, Grelecki G, Biłgorajski A, Podwalski P, Misiak B, Samochowiec J. Effect of antipsychotic treatment on neutrophil-to-lymphocyte ratio during hospitalization for acute psychosis in the course of schizophrenia—a cross-sectional retrospective study. Journal of Clinical Medicine. 2021;11(1):232. [DOI:10.3390/jcm11010232.]
23. Messina A, Bella F, Maccarone G, Rodolico A, Signorelli MS. Neutrophil-Lymphocyte Ratio Values in Schizophrenia: A Comparison between Oral and Long-Acting Antipsychotic Therapies. Brain Sci. 2024;14(6):602. [DOI:10.3390/brainsci14060602.]
24. Zhou X, Wang X, Li R, Yan J, Xiao Y, Li W, et al. Neutrophil-to-lymphocyte ratio is independently associated with severe psychopathology in schizophrenia and is changed by antipsychotic administration: a large-scale cross-sectional retrospective study. Frontiers in psychiatry. 2020;11:581061. [DOI:10.3389/fpsyt.2020.581061.]
25. Birnbaum R, Weinberger DR. A Genetics Perspective on the Role of the (Neuro)Immune System in Schizophrenia. Schizophr Res. 2020;217:105–13. [DOI:10.1016/j.schres.2019.02.005.]
26. İnaltekin A, Yağcı İ. Evaluation of simple markers of inflammation and systemic immune inflammation index in schizophrenia, bipolar disorder patients and healthy controls. Turkish Journal of Psychiatry. 2021;34(1):11. [DOI:10.5080/u26248.]
27. Bradburn S, Murgatroyd C, Ray N. Neuroinflammation in mild cognitive impairment and Alzheimer’s disease: A meta-analysis. Ageing research reviews. 2019;50:1–8. [DOI:10.1016/j.arr.2019.01.002.]
28. Misiak B, Stanczykiewicz B, Kotowicz K, Rybakowski JK, Samochowiec J, Frydecka D. Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: A systematic review. Schizophr Res. 2018;192:16–29. [DOI:10.1016/j.schres.2017.04.015.]
29. Karageorgiou V, Milas GP, Michopoulos I. Neutrophil-to-lymphocyte ratio in schizophrenia: A systematic review and meta-analysis. Schizophr Res. 2019;206:4–12. [DOI:10.1016/j.schres.2018.12.017.]
30. Goyal MK, Solanki RK, Jain A, Yadav KS. Comparison of NLR (neutrophil/lymphocyte ratio) and PLR (platelet/lymphocyte ratio) as inflammatory markers in 1(st) episode mania and bipolar mania: A preliminary study. Indian J Psychiatry. 2023;65(4):465–8. [DOI:10.4103/indianjpsychiatry.indianjpsychiatry_250_22.]
31. Mazza MG, Lucchi S, Tringali AGM, Rossetti A, Botti ER, Clerici M. Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in mood disorders: A meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2018;84(Pt A):229–36. [DOI:10.1016/j.pnpbp.2018.03.012.]
32. Krzemien G, Panczyk-Tomaszewska M, Kotula I, Demkow U, Szmigielska A. Diagnostic accuracy of urine neutrophil gelatinase-associated lipocalin and urine kidney injury molecule-1 as predictors of acute pyelonephritis in young children with febrile urinary tract infection. Cent Eur J Immunol. 2019;44(2):174–80. [DOI:10.5114/ceji.2019.87069.]
33. Chen K, Wang L, Ning H, Pan H, Zhang W. Neutrophil-to-lymphocyte ratio; platelet-to-lymphocyte ratio; systemic immune-inflammatory Index: inflammatory indicators of cognitive impairment in schizophrenia patients. Front Psychiatry. 2025;16:1552451. [DOI:10.3389/fpsyt.2025.1552451.]
34. Koupenova M, Clancy L, Corkrey HA, Freedman JE. Circulating Platelets as Mediators of Immunity, Inflammation, and Thrombosis. Circ Res. 2018;122(2):337–51. [DOI:10.1161/CIRCRESAHA.117.310795.]
35. Brzezinski-Sinai NA, Brzezinski A. Schizophrenia and Sex Hormones: What Is the Link? Frontiers in Psychiatry. 2020;Volume 11 - 2020. [DOI:10.3389/fpsyt.2020.00693.]
36. Xu H, Wei Y, Zheng L, Zhang H, Luo T, Li H, et al. Relation Between Unconjugated Bilirubin and Peripheral Biomarkers of Inflammation Derived From Complete Blood Counts in Patients With Acute Stage of Schizophrenia. Front Psychiatry. 2022;13:843985. [DOI:10.3389/fpsyt.2022.843985.]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |